Manufacture of bulk drugs at the heart of what we do
India’s first company to start commercial production of Anti-tuberculosis drug Rifampicin
Gujarat Themis Biosyn Limited was incorporated in 1981 as a joint sector company with GIIC Ltd. and Chemosyn (P) Ltd. It commenced production in August 1985. It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is being actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007.
News Corner
1. The Income from operations of Gujarat Themis Biosyn Limited (A BIRF Company) is as per the plan envisaged by the Management of the Company utilizing capacity to the fullest extent.
2. The Income from operations during the year ended 31st March, 2015 stood at Rs.3144.02 lakhs as compared to Rs. 3023.03 lakhs during the year ended 31st March, 2014.
3. Net Profit improved to Rs. 459.41 lakhs during the period under consideration compared to Rs. 452.60 lakhs during the last year.
4. EPS (Basic) at Rs. 3.16 for the current year compared to Rs. 3.12 during the last year.
5. Barring unforeseen circumstances, the Company expects to wipe off the negative net worth in 2015-16 much before the period for which the revival scheme is approved by BIFR.
Annual Report 2013 – 2014